Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CHIR-124 + Irinotecan|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CHIR-124||CHIR124||CHK1 Inhibitor 15||CHIR-124 is a selective inhibitor of CHK1, which may enhance sensitivity of tumor cells to chemotherapeutic agents (PMID: 17255282, PMID: 22244109).|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 10||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TP53 inact mut||breast carcinoma||predicted - sensitive||CHIR-124 + Irinotecan||Preclinical - Cell line xenograft||Actionable||In a preclinical study, sequential treatment with Camptosaur (irinotecan) and CHIR-124 enhanced tumor growth inhibition compared to either agent alone in a breast carcinoma cell line xenograft model with defective TP53 (PMID: 17255282).||17255282|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|